Disease · MONDO_0017276
frontotemporal dementia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. frontotemporal dementia. Diseases, record MONDO_0017276. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017276
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 3 of its 18 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs18
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LATOZINEMAB | CHEMBL4650439 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| MEMANTINE | CHEMBL807 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| HYDROMETHYLTHIONINE MESYLATE | CHEMBL4297221 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYTOCIN | CHEMBL395429 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| GALANTAMINE | CHEMBL659 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LITHIUM CARBONATE | CHEMBL1200826 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NABILONE | CHEMBL2218896 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILUZOLE | CHEMBL744 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 18
See all 18 drugsTargets89
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | 2 | Gonadotropin-releasing hormone receptor agonist | Unknown | https://conductscience.org/library/genes/2798 | Drugs and targets |
| PIKFYVE | 1-phosphatidylinositol 3-phosphate 5-kinase | 2 | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor | Unknown | https://conductscience.org/library/genes/200576 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor agonist | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| COMT | Catechol O-methyltransferase | 1 | Catechol O-methyltransferase inhibitor | Phase 2 | https://conductscience.org/library/genes/1312 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
1 to 10 of 89
See all 89 targetsTrials22
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02118727 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | Phase 2 | 89 | 2022-11-29 | Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia | MEMANTINE, RILUZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04220021 | Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | Phase 2 | 41 | 2025-12-02 | C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia | METFORMIN | Its record names the disease | ClinicalTrials.gov |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Phase 2 | 33 | 2025-08-22 | Frontotemporal Dementia | LATOZINEMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00604591 | Effects of Tolcapone on Frontotemporal Dementia | Phase 2 | 28 | 2024-08-28 | Frontotemporal Lobar Degeneration | TOLCAPONE | Its record names the disease | ClinicalTrials.gov |
| NCT02862210 | Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia | Phase 2 | 17 | 2025-02-03 | Frontotemporal Dementia (FTD) | LITHIUM CARBONATE | Its record names the disease | ClinicalTrials.gov |
| NCT04115384 | Intranasal Insulin in Frontotemporal Dementia (FTD) | Phase 2 | 3 | 2023-07-06 | Frontotemporal Dementia, Behavioral Variant | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT01626378 | Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | 220 | Behavioral Variant Frontotemporal Dementia (bvFTD) | HYDROMETHYLTHIONINE MESYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Phase 3 | 119 | Frontotemporal Dementia | LATOZINEMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03260920 | Intranasal Oxytocin for Frontotemporal Dementia | Phase 2 | 112 | Frontotemporal Dementia | OXYTOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05288842 | Tanycytes in Alzheimer's Disease and Frontotemporal Dementia | 102 | Alzheimer Disease, Frontotemporal Dementia | GONADORELIN, GONADORELIN ACETATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Memantine vs Placebo: deaths from any cause | 3 of 58 | 3 of 31 | 89 | NCT02118727 | Trial comparisons |
| Memantine vs Placebo: serious adverse events | 8 of 58 | 3 of 31 | 89 | NCT02118727 | Trial comparisons |
| Enrolled Subjects vs Study Completers: deaths from any cause | 0 of 41 | 0 of 23 | 64 | NCT04220021 | Trial comparisons |
| Study Completers vs All Participants: Number of Subjects With Unexpected Treatment-emergent Adverse Events [Safety and Tolerability] | 0 of 23 | 0 of 41 | 64 | NCT04220021 | Trial comparisons |
| Enrolled Subjects vs Study Completers: serious adverse events | 2 of 41 | 0 of 23 | 64 | NCT04220021 | Trial comparisons |
| Lithium Carbonate vs Placebo: Number of Responders in the Lithium and Placebo Groups | 0 of 9 | 0 of 7 | 16 | NCT02862210 | Trial comparisons |
| Lithium Carbonate vs Placebo: deaths from any cause | 0 of 9 | 0 of 7 | 16 | NCT02862210 | Trial comparisons |
| Lithium Carbonate vs Placebo: serious adverse events | 2 of 9 | 0 of 7 | 16 | NCT02862210 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0017276
GET https://conductscience.org/api/diseases/v1/MONDO_0017276/targets?page=2